<DOC>
	<DOC>NCT00482703</DOC>
	<brief_summary>The objective is to evaluate the cytogenetic response to Dasatinib (BMS-354825) administered for 24 weeks in subjects with Imatinib resistant or intolerant chronic phase chronic myeloid leukemia (CML) once daily (QD) or twice daily. (BID)</brief_summary>
	<brief_title>A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Philadelphia chromosome positive or bcrabl gene positive Chronic phase Chronic Myelogenous Leukemia (CML) subjects must have primary or acquired resistance to Imatinib mesylate or have intolerance of imatinib mesylate Performance status (general conditions) specified by the Eastern Cooperative Oncology Group: 02 Men and women, ages 20 to 75 Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 3 months after the study in such a manner that the risk of pregnancy is minimized Subjects who are eligible and willing to undergo transplantation at prestudy Women who are pregnant or breastfeeding Uncontrolled or significant cardiovascular disease History of significant bleeding disorder unrelated to CML Adequate hepatic function Adequate renal function Medication that increases bleeding risk Medication that changes heart rhythms Subjects who are compulsory detained for legal reasons or treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Imatinib resistant or intolerant chronic phase CML</keyword>
</DOC>